VA Induction and Bridging Transplantation for Hypoplastic/Secondary AML
A Multicenter, Single-arm Clinical Study of Venetoclax Combined With Azacitidine Induction and Bridging to Allogeneic Hematopoietic Stem Cell Transplantation for the Treatment of Hypoplastic or Secondary Acute Myeloid Leukemia
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Intervención / Tratamiento
Intervención / Tratamiento
Descripción detallada
Tipo de estudio
Tipo de estudio
Inscripción (Estimado)
Inscripción
Fase
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
Estudio Contacto
- Nombre: Zhen Shen, Doctor
- Número de teléfono: 0512-67976802
- Correo electrónico: zhenshen96@sina.cn
Ubicaciones de estudio
-
-
Jiangsu
-
Suzhou, Jiangsu, Porcelana, 215000
- The First Affiliated Hospital of Soochow University
-
-
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
- Adulto
- Adulto Mayor
Acepta Voluntarios Saludables
Descripción
Inclusion Criteria:
- Age ≥18 years.
- Previously untreated acute myeloid leukemia (AML) diagnosed according to the 2022 ELN guidelines. Patients with isolated extramedullary disease (i.e., no evidence of AML in bone marrow or peripheral blood) are not eligible.
- Bone marrow biopsy demonstrating cellularity <20% or concurrent myelofibrosis; Or a prior history of an antecedent hematologic disorder, radiotherapy/chemotherapy-related history, or presence of myelodysplasia-related changes (AML-MRC according to WHO-HEAM5).
- The patient is deemed suitable for allogeneic hematopoietic stem cell transplantation as assessed by the treating physician.
- Adequate organ function, defined as follows: a. Good liver function: serum total bilirubin ≤2.0 × upper limit of normal (ULN); if considered due to Gilbert's disease or leukemia, serum total bilirubin <3.0 × ULN. Aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase (ALP) ≤3.0 × ULN, unless considered due to leukemia. b. Good renal function: serum creatinine ≤2.0 × ULN or creatinine clearance >30 mL/min calculated using the Cockcroft-Gault formula. c. No history of chronic lung disease and no dyspnea. Otherwise, documented diffusing capacity of the lung for carbon monoxide ≤40% (adjusted for hemoglobin if available) and forced expiratory volume in 1 second/forced vital capacity ≥50%.
- ECOG performance status score 0-2.
- Ability to understand and voluntarily sign informed consent.
- Women of childbearing potential must have a negative serum pregnancy test before initiation of study treatment.
Exclusion Criteria:
- Prior treatment for AML, except non-cytotoxic therapy given to stabilize disease.
- White blood cell count ≥10×10⁹/L, or presence of proliferation-associated gene mutations such as FLT3.
- Favorable risk group according to the 2022 ELN prognostic stratification, e.g., t(8;21), inv(16)/t(16;16), NPM1 mutation, or CEBPA bZIP in-frame mutation.
- No suitable stem cell donor available.
- Acute promyelocytic leukemia (APL).
- Clinical symptoms suggestive of active central nervous system (CNS) leukemia or known CNS leukemia.
- Life-threatening immediate complications of leukemia, such as uncontrolled bleeding, hypoxic pneumonia, sepsis, and/or disseminated intravascular coagulation (DIC). Expected survival <12 weeks.
- Prior allogeneic hematopoietic stem cell transplantation for a hematologic disorder.
- Current use of strong CYP3A4 inducers or narrow-therapeutic-window CYP3A4 substrates; enrollment is allowed only if these drugs can be switched to alternatives ≥5 half-lives before the first dose of study treatment.
- Active, uncontrolled systemic fungal, bacterial, or viral infection despite appropriate antibiotic, antiviral, or other therapy.
- Known infection with human immunodeficiency virus (HIV) or active hepatitis B virus (HBV) or hepatitis C virus (HCV) that cannot be controlled by therapy.
- Another active malignancy, unless the patient has been disease-free for ≥5 years before initiation of study treatment. However, patients with the following history/concurrent conditions or similar indolent cancers are eligible: Basal cell or squamous cell carcinoma of the skin Carcinoma in situ of the cervix Carcinoma in situ of the breast Prostate cancer found incidentally on histology.
- Significant active cardiac disease within 6 months before initiation of study treatment, including New York Heart Association (NYHA) Class III or IV congestive heart failure, myocardial infarction, unstable angina, and/or stroke.
- Uncontrolled hypertension (systolic blood pressure >180 mmHg or diastolic blood pressure >100 mmHg).
- Dysphagia, short-bowel syndrome, gastroparesis, or other conditions that limit oral intake or gastrointestinal absorption.
- Known history of progressive multifocal leukoencephalopathy (PML).
- Known hypersensitivity to any component of venetoclax or azacitidine.
- Female patient who is pregnant or breastfeeding.
- Any other medical or psychological condition that, in the investigator's opinion, could interfere with the patient's ability to sign informed consent or participate in the study.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Número de brazos
Armas e Intervenciones
Grupo de participantes/brazoGrupo de participantes/brazo |
Intervención / TratamientoIntervención / Tratamiento |
|---|---|
|
Experimental: A
VA induction+Allo-HSCT consolidation
|
Venetoclax was administered at 100 mg on day 1, 200 mg on day 2, and 400 mg on days 3-28 of cycle 1.
Azacitidine was administered at 75 mg/m² on days 1-7 of cycle 1.
All patients proceeded directly to allogeneic HSCT after cycle 1, regardless of remission.
Myeloablative or intensified conditioning was preferred; reduced-intensity conditioning was allowed for intolerant patients.
Donor source and transplant type were not restricted.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Overall Survival (OS)
Periodo de tiempo: 2 year
|
Time from the date of diagnosis to death due to any cause.
|
2 year
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Complete Remission Rate(CRR)
Periodo de tiempo: Day 28 of induction therapy and 56 days post-transplantation
|
Bone marrow blasts <5%, absence of extramedullary disease, no circulating blasts, peripheral blood neutrophil count ≥1.0×10⁹/L, platelet count ≥100×10⁹/L, independent of transfusion or growth factor support.
|
Day 28 of induction therapy and 56 days post-transplantation
|
|
Composite Complete Remission Rate (CCRR)
Periodo de tiempo: Day 28 of induction therapy and 56 days post-transplantation
|
The proportion of patients achieving complete remission (CR), complete remission with incomplete hematologic recovery (CRi), or complete remission with partial hematologic recovery (CRh).
|
Day 28 of induction therapy and 56 days post-transplantation
|
|
Disease-free Survival (DFS)
Periodo de tiempo: 2 year
|
Time from achieving disease remission to disease relapse or death from any cause.
|
2 year
|
|
GVHD-free and Relapse-free Survival (GRFS)
Periodo de tiempo: 2 year
|
Time from transplant date to the first occurrence of grade III-IV acute GVHD, chronic GVHD requiring systemic treatment, disease relapse, or death from any cause.
|
2 year
|
|
Cumulative Incidence of Relapse (CIR)
Periodo de tiempo: 2 year
|
Time from transplant date to disease relapse.
|
2 year
|
|
Non-relapse Mortality (NRM)
Periodo de tiempo: 2 year
|
Time from transplant date to death due to non-relapse/progression causes.
|
2 year
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Colaboradores
Colaboradores
Investigadores
Investigadores
- Investigador principal: Suning Chen, Doctor, The First Affiliated Hospital of Soochow University
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Estimado)
Inicio del estudio
Finalización primaria (Estimado)
Finalización primaria
Finalización del estudio (Estimado)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
Otros números de identificación del estudio
- 2026531
- 09021420250003 (Otro número de subvención/financiamiento: Suzhou University Affiliated First Hospital 'Yanzhen Lingfei' Program)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .